TRIB

Trinity Biotech plc (TRIB) Risks & Opportunities Analysis (2026)

Invetso Score: 3.3/10 — Weak · Last Updated: 2026-09-01

Monthly Update

No material changes this month.

Risks

Score: 2.1 (Weak)

Liquidity is extremely tight, with a 0.25 current ratio and 0.12 quick ratio, leaving TRIB far more exposed than better-capitalized peers to working-capital shocks and refinancing stress.

Interest coverage is negative and net debt to EBITDA is deeply negative, indicating operating losses and leverage pressure that constrain flexibility versus profitable peers with self-funding balance sheets.

Inventory days of 243 and receivables days of 86 suggest slow cash conversion, so TRIB faces materially weaker cash generation than peers with faster turns and stronger liquidity.

Payables days of 383 imply heavy supplier financing, which can support near-term cash but raises counterparty and supply-chain risk versus peers with more balanced working-capital structures.

Opportunities

Score:

The negative cash conversion cycle indicates supplier financing is currently offsetting inventory and receivables drag, which can preserve liquidity better than peers with less favorable working-capital terms.

If demand stabilizes, TRIB has room for operating leverage from its stretched working-capital base, creating more upside than peers already operating with efficient cash cycles.

The absence of meaningful debt-service burden from a negative net debt to EBITDA position can support relative resilience versus levered peers if operating performance improves.

Any improvement in inventory turns would release substantial cash because current inventory days are elevated, giving TRIB more near-term upside than peers with leaner stock positions.

Overall Score

Score:

TRIB’s forward positioning is constrained by severe liquidity and coverage pressure, while opportunities are limited to working-capital normalization and operating leverage versus peers.

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on Trinity Biotech plc. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →